EP
PASG icon

Eversept Partners’s Passage Bio PASG Stock Holding History

Eversept Partners’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Buy
131,581
+5,351
+4% +$55.4K 0.05% 108
2025
Q4 		$1.49M Buy
+126,230
New +$1.09M 0.08% 95

Other funds holding PASG

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Eversept Partners's PASG Position: Q1 2026 in Review

Eversept Partners increased its Passage Bio (PASG) stake by 4.2% in Q1 2026, buying an estimated $55.4K and bringing the position to 131,581 shares worth $1.03M. The position accounts for 0.05% of the portfolio, ranked #108.

Eversept Partners first reported a position in PASG in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.49M in Q4 2025. 35 funds tracked by Wall St. Rank hold PASG as of Q1 2026.

  • Eversept Partners held 131,581 shares of Passage Bio worth $1.03M as of Q1 2026.
  • Eversept Partners bought 5,351 Passage Bio shares in Q1 2026, an estimated $55.4K.
  • Passage Bio made up 0.05% of Eversept Partners's portfolio in Q1 2026, its #108 holding.
  • Eversept Partners first reported a position in Passage Bio in Q4 2025 and has held it in 2 quarters since.
  • Eversept Partners's Passage Bio position peaked at $1.49M in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Passage Bio as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.